Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Apellis Pharmaceuticals, often referred to simply as Apellis, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, the company has made significant strides in the field of complement biology, focusing on innovative therapies for rare diseases and serious conditions. With a strong operational presence in North America and Europe, Apellis is dedicated to transforming the treatment landscape for patients with unmet medical needs.
The company’s flagship product, pegcetacoplan, is a groundbreaking therapy designed to address conditions such as paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration. Apellis stands out in the industry for its commitment to advancing complement inhibition, positioning itself as a pioneer in this specialised area. With a robust pipeline and a focus on patient-centric solutions, Apellis Pharmaceuticals continues to solidify its reputation as a key player in the biopharmaceutical sector.
-19 vs industry average
Apellis Pharma’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Apellis Pharma yet.
Apellis Pharma, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges available from the company.
As a result, Apellis Pharma's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent company or corporate family. The company may still be in the process of developing its sustainability strategies or reporting frameworks.
In the context of the pharmaceutical industry, many companies are increasingly focusing on reducing their carbon footprints and setting science-based targets to align with global climate goals. However, without specific data or commitments from Apellis Pharma, it is challenging to assess their current standing in this regard.
No climate goals have been disclosed for Apellis Pharma yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more